报价延迟最少15分钟:2026/09/19 12:40 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.48 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.25/1.06
|
|
企业价值
838.13M
|
| 资产负债 |
|
每股账面净值
-4.26
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
175.11M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
